Napoleone Ferrara
Independent Director & Co-FounderProf. Dr. Napoleone Ferrara, M.D., serves as Member of Scientific Advisory Board of Abilita Therapeutics, Inc. He serves as Venture Partner of Catalio Capital Management, LP. He is an Independent Director at Kalaris Therapeutics, Inc. since September 2019 and also its Co-Founder. He is a Co-Founder of Theia Therapeutics and NVasc, Inc. Prof. Dr. Ferrara is a Member of Board of Directors of DelMar Pharmaceuticals and Inflammosome Therapeutics. He serves as a Director of Inflammosome Therapeutics, Inc. He serves as a Member of Scientific Advisory Board at 4D Molecular Therapeutics, Inc. since 2024, Atengen, Gemini Therapeutics since August 2020 and He served as a Member of Scientific Advisory Board at OKYO Pharma Limited since August 2020 until 2026. Prof. Dr. Ferrara has been a Consultant and Member of Scientific Advisory Board at Tiziana Life Sciences PLC since October 2022. He is a Distinguished Professor of Ophthalmology, University of California, focusing on Anti-Angiogenic Therapies and Therapies for Intraocular Vascular Disorders. He is a Distinguished Professor of Pathology at the University of California since January 2013 and a Distinguished Adjunct Professor of Ophthalmology at the University of California's School of Medicine since July 2014. He is a Senior Deputy Director for Basic Sciences at University of California’s Moores Cancer Center. Prof. Dr. Ferrara served as a Director of Kintara Therapeutics, Inc. from June 22, 2018 until August 19, 2020. He also served as Chairman of Scientific Advisory Board of Kintara Therapeutics, Inc. and as its Member of Scientific Advisory Board since April 4, 2019. He served as a Director of Tuhura Biosciences, Inc. (formerly, DelMar Pharmaceuticals, Inc.) from June 2018 to August 2020. Prof. Dr. Ferrara served as a Member of Scientific Advisory Board at Neovacs SA and Tiziana Life Sciences PLC. He held increasingly senior positions at Genentech, Inc., including fellow, staff scientist and senior scientist. Prof. Dr. Ferrara focuses on Anti-Angiogenic Therapies and Therapies for Intraocular Vascular Disorders. He is a pioneer in the study of angiogenesis biology and identification of its regulators. Prof. Dr. Ferrara’s research led to the development of the anti-VEGF monoclonal antibody bevacizumab. Prof. Dr. Ferrara’s lab is responsible for discovering the isolation and cDNA cloning of VEGF and demonstrated that VEGF was a major mediator of tumor angiogenesis leading to the development of Avastin. Prof. Dr. Ferrara’s lab’s studies led to the clinical development of an anti-VEGF antibody fragment, Lucentis, as a highly effective therapy preventing vision loss in intraocular neovascular disorders. He possesses extensive experience in clinical development of monoclonal antibodies, which has been useful in the formulation and clinical development of Foralumab, a fully human anti-CD3 monoclonal antibody, as well as other immunotherapy projects. Prof. Dr. Ferrara received fellowship training and postdoctoral research from the University of California, San Francisco. He received a Doctor of Medicine and residency training from the University of Catania Medical School. He received a Maturita' Classica from LiCEO Classico Mario Cutelli.
公司职务
- 公司名称Kalaris Therapeutics, Inc.股票代码KLRS职务Independent Director & Co-Founder
- 公司名称Tiziana Life Sciences Ltd股票代码TLSA职务Member of Scientific Advisory Board共事同僚
- GMGabriele Marco Antonio CerroneFounder & Executive Chairman
- KSKeeren ShahCOO & CFO
- IRIvor R. ElrifiCEO & Executive Director
- WEWilliam Edward TenteChief Regulatory Officer
- RKRichard K. KimChief Medical Officer
- WJWilly Jules SimonIndependent Non-Executive Director
- JPJohn Patrick BrancaccioIndependent Non-Executive Director
